Alnylam Pharmaceuticals Inc

ALNY

$224.91

+78.0% last 12 months

Stanley Druckenmiller Holding value: $20 Million Ken Griffin Holding value: $18.6 Million Steven Cohen Holding value: $3.28 Million Joel Greenblatt Holding value: $761 Thousand Ray Dalio Holding value: $289 Thousand Julian Robertson Holding value: $0 Jim Simons Holding value: $0 Tom Russo Holding value: $0 Cathie Wood Holding value: $0 George Soros Holding value: $0

Market Cap

$28.5 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$117.58 - $242.97

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

-24.1x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $28.5 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $27.2 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $0.00 (0.0%)
1 Year Return Profit or loss of share price change plus dividend yield. +78.0%
52-Week High Highest share price in the last 52 weeks. $242.97
52-Week Low Lowest share price in the last 52 weeks. $117.58
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 1.02
Outstanding Shares The number of shares the company has issued and are held by stockholders. 123 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 703 Thousand

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. -24.1
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. -24.47
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. -$9.78
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 32.13
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company -224.91
Enterprise Value to Revenue Enterprise value divided by revenue 28.35
Enterprise Value to EBIT Enterprise Value divided by EBIT -34.44
Total Debt to Enterprise Value Total debt divided by enterprise value 0.04
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. -15.02

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $961 Million
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $806 Million
EBIT Earnings before tax and interest payments. -$791 Million
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. -$1.18 Billion
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. -123.02%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. +98.5%
Return on Equity Equity divided by market cap. 1747.72%
Return on Assets Indicates a company's profitability in relation to its total assets. -33.44%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. -28.63%

Insider trades

No purchases

No sells

No purchases

1,754.0 shares sold (1 transactions)

No purchases

No sells

No purchases

No sells

Q2 2022 Q3 2022 Q4 2022 Q1 2023

About Alnylam Pharmaceuticals Inc

CEO: John Maraganore

Industry: Pharmaceutical Preparation Manufacturing

Similar stocks

Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Sarepta Therapeutics Inc
Sarepta Therapeutics Inc
Opko Health Inc
Opko Health Inc
Novartis AG - ADR
Novartis AG - ADR
Sanofi - ADR
Sanofi - ADR
Teva- Pharmaceutical Industries Ltd. - ADR
Teva- Pharmaceutical Industries Ltd. - ADR

News

ALNY (Alnylam Pharmaceuticals Inc.) has powerful results

ALNY (Alnylam Pharmaceuticals Inc.) has powerful results

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) closed Thursday at $231.59 per share, up from $229.02 a day earlier. While Alnylam Pharmaceuticals Inc. has overpe...

US Post News US Post News, 7 days ago
ClearBridge Select Strategy Q4 2022 Portfolio Manager Commentary (undefined:ALNY)

ClearBridge Select Strategy Q4 2022 Portfolio Manager Commentary (undefined:ALNY)

ClearBridge is a leading global asset manager committed to active management.

Seeking Alpha Seeking Alpha, 12 days ago
Novartis AG – Consensus Indicates Potential 13.1% Upside

Novartis AG – Consensus Indicates Potential 13.1% Upside

Novartis AG found using ticker (NVS) have now 4 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target pric...

DirectorsTalk DirectorsTalk, 14 days ago
Alnylam Pharmaceuticals In-Line Revenue & A Full Slate Of Clinical Read-Outs (ALNY)

Alnylam Pharmaceuticals In-Line Revenue & A Full Slate Of Clinical Read-Outs (ALNY)

Alnylam shares have continued to outperform since my last update, besting the XBI ETF by about 10%. Find out why I''m bullish on ALNY stock.

Seeking Alpha Seeking Alpha, 24 days ago
Never miss a trade
To improve your user experience we use cookies.